In Australia, Icon acknowledges the Traditional Custodians of the lands where we operate. We recognise and celebrate the diversity of Indigenous peoples, their enduring cultures and respect that these lands and waters have long been places of healing.This report was prepared on the lands of the Yuggera and Turrbal people in South Brisbane.
Across Icon Group, we acknowledge and respect the history and contributions of First Nations peoples.
As a global organisation, we honour and respect Indigenous cultures around the world and recognise and value the strength of Indigenous knowledge in helping us provide the best care possible.
Image: Photo of the Traditional Yuggera and Turrbal country of Meanjin (Brisbane)
CEO foreword
At Icon Group, we believe access to high-quality healthcare should not depend on geography, circumstance or background. Since our foundation, our mission has remained steadfast: to deliver the best possible care, to as many people as possible, as close to home as possible.
We are committed to helping close the cancer care gap, one patient and one community at a time.
Our 2025 Impact Report captures the collective achievements of our global team this past financial year. It shows we’re expanding access to world-class, personalised healthcare and advancing research to shape the future of oncology, and introducing innovations to drive meaningful outcomes for patients, families and communities.
Together, we:
• Supported more than four million patient interactions across Australia, New Zealand, Mainland China, ASEAN, and the United Kingdom
• Announced 12 new locations and acquired Cancer Centre London
• Acquired UK-based Pharmaxo Group to extend our compounding footprint and introduce home care services into Icon
• Introduced Icon’s integrated model of care in Indonesia and deepened our services into Malaysia
• Introduced advanced technology including the announcement of Gamma Knife centres and opening of our first CyberKnife centre with joint venture partner, 5D Clinics
• Provided patient care that earned a Net Promoter Score of 95 in Australia- a remarkable endorsement of the dedication and trust that defines our teams.
From pioneering technologies to expanding clinical trials, from opening new centres to forming strategic partnerships in emerging regions—our teams continue to prove what’s possible when purpose, expertise, and care align.
Sustainability is central to how we operate globally. We’re building on our ESG roadmap to reduce our environmental impact, promote diversity and inclusion, and improve care access in underserved communities.
As we now mark Icon Group’s 10-year anniversary, we carry with us lessons gained from a decade of collaborative service, care and innovation, while building on the extensive history of the businesses that came together to form what Icon is today.
Most importantly, we look forward to a future where more people can receive the care they need, closer to where they live. Because, while we cannot eliminate every barrier overnight, we can work every day to ensure that where you live doesn’t determine the standard of your care.
To our patients – thank you for trusting us. To our partners – thank you for your ongoing support. And to our teams around the world –thank you for your dedication to providing the best care, every day.
Together, we are making a lasting difference and turning the dial on the global cancer burden.
Mark Middleton OAM Icon Group CEO
About Icon Group
Icon Group is a world-leading integrated cancer care provider operating across Australia, New Zealand, Singapore, Malaysia, Indonesia, Mainland China, and the United Kingdom.
With a global network of over 55 cancer centres, six compounding facilities and the management of more than 70 hospital pharmacies, we care for patients across all aspects of cancer treatment, research, pharmacy and compounding.
Our 3,800+ employees, including more than 370 doctors and medical specialists, share a common purpose - to bring the best care to every patient, closer to home.
Sunsuria
MAINLAND CHINA
Partnership with Bali International Hospital
MALAYSIA
SINGAPORE
INDONESIA
One cancer centre
Delivers support services for 70+ pharmacies
43+ cancer centres
23 centres delivering research
Drug stability and research lab
Four TGA licensed compounding facilities
AUSTRALIA
NEW ZEALAND
Six cancer centres including flagship Mt Alvernia integrated centre
Three centres delivering research
One health screening centre
One cancer centre
Research capabilities
One GMP licensed compounding facility
FY24/25 Highlights
New Geographies
New sites openings and announcements across Australia, Malaysia, Indonesia and the UK
12
Expanded our UK presence acquiring Pharmaxo Group and Nuffield Health Cancer Centre London
Formed European Board Committee to drive UK partnerships, enhance cancer care
Deepened care in ASEAN through partnership with Bali International Hospital and grown to two centres in Malaysia with our partners, IHH Healthcare.
Joined International Hospital Federation (IHH) Premier Associate Member to drive global impact
Won Singapore AustCham Business Excellence Awards
Slade Health Woodville, South Australia marked one year of excellence in compounding
Future Healthcare
First in southern hemisphere, third in world to introduce Varian’s RapidArc Dynamic
Introduced game changing CyberKnife and announced Gamma Knife technology
100% stereotactic enabled across Icon’s global network
200+
Clinical trials active across 28 locations, with over 200 new patient enrolments
Launched a theranostics research program and expanded molecular imaging services to advance precision cancer care
Expanded and strengthened Slade Pharmacy national network under one brand
Celebrated 60 years of Slade healthcare excellence
$18.7M USD investment in Varian cutting-edge radiotherapy imaging and software across UK
Extended patient support through partnerships with: - Bowel Cancer Australia - Omico
- Prostate Cancer Foundation - Radformation
- Rare Cancers Australia
- Singapore 365 Cancer Prevention Society
Listed
Care for patient, people and planet
Delivered
4,000,000+
patient interactions globally
Quality care –95 NPS Score (AU)
GCSA global accreditation
Achieved
Delivered 16,000+ cancer care connections to people in at-risk communities through programs and advocacy partnerships
Recognised clinical leaders:
Dr Penny Kechagioglou Oncologist of the Year
A/Prof Louise Nott Australian of the Year Finalist
Prof Michael Poulsen AM, Dr Gerald Fogarty OAM King’s Birthday Honours
Expanded award winning survivorship care program across Australia in Scope 1 and 2 emissions, meeting our interim sciencebased target Launched our first Sustainability Report 49% reduction
Our Impact
My doctor and team created an environment where you feel cared for, not just treated”
-Paul Butcher, patient at the newly opened Icon Cancer Centre The Bays, Victoria
Australia and New Zealand
Expanding access to cancer care across metro and regional Australia
Across Australia and New Zealand, Icon has significantly grown its footprint. We are bringing world-class cancer care closer to more homes, reducing travel burdens, improving access to comprehensive care, introducing advanced technologies and maturing our hospital pharmacy and specialised compounding services.
Opened three new Icon Cancer Centre locations CANCER CARE HIGHLIGHTS
Noosa, QLD
Opened mid-2024 at Stockwell’s Civic Medihub. This centre offers Varian TrueBeam linear accelerator, HyperArc, stereotactic radiation therapy, tattoo-free treatment, and SGRT*. It has the capacity to deliver 900 radiation treatment courses annually.
*See glossary page 60
Ipswich, QLD
Opened mid-2025 inside St Andrew’s Ipswich Private Hospital. The centre integrates radiation oncology, pharmacy, and allied health services, in partnership with Ipswich Private Hospital with technologies including HyperArc and DIBH. Rounds out Icon’s strong Queensland origins.
The Bays, VIC
Opened in January 2025. This centre marked Icon’s continued expansion across Victoria and outer-metro locations, increasing access to local cancer care. It offers Varian TrueBeam including HyperArc, stereotactic radiation therapy, DIBH and tattoo-free treatment.
New centres and pioneering treatments
Investing in South Australia
New Icon Cancer Centre announced in North Adelaide, offering advanced radiation oncology services.
Cutting-edge technology
CyberKnife – advanced treatment introduced through a joint venture with 5D Clinics. Marks the first CyberKnife on Australia’s eastern seaboard and only third nationally.
Precision oncology
Gamma Knife – announced to open at Herston, Brisbane. Cutting-edge specialised treatment technology announced, delivering advanced treatment for neurological, cranial, and brain conditions. Marks the first private Leksell Gamma Knife facility in Queensland and only fourth nationally.
Eighty Eight O-Connell Precinct where Icon Cancer Centre North Adelaide will open.
CyberKnife at 5D Clinics Cremorne, Melbourne.
Gamma Knife announced in Herston, Brisbane.
Delivering more care in the west
New Icon Cancer Centre announced, offering advanced radiation oncology services at St John of God Hospital, Subiaco.
Building capacity
Second linear accelerator’s installed at Icon Cancer Centre locations at Hobart, Tasmania, Midland in Western Australia and Rockingham’s second linac opening in FY25/26, delivering more care to more people.
Installation of second Varian TrueBeam linac at Icon Cancer Centre Midland.
St John of God Hospital, Subiaco, Western Australia
Technology leadership
Icon continues to lead innovation across its cancer care network:
• First in Australia and the Southern Hemisphere to introduce Varian’s RapidArc Dynamic (RAD), now available at Icon Cancer Centre Midland, WA.
• HyperArc, stereotactic treatments and use of Radformation’s AI delivered and rolled out at multiple sites for efficient, high-precision patient care. Stereotactic rollout has been implemented across 100% of Icon’s cancer centres.
• Further evolutions to SGRT (Surface Guided Radiation Therapy) and DIBH (Deep Inspiration Breath Hold) implemented across the network to improve patient comfort and outcomes building on Icon’s advanced technology suite.
• Signed a Centre of Excellence Agreement with Radformation building out our strategic partnership and recognising Icon as expert users of automation software.
Icon Cancer Centre Midland team with Varian representatives on the launch of RapidArc Dynamic.
Group Executive Manager – Clinical Care, Trent Aland receiving Radformation’s Centre of Excellence certification.
Doctor recognition and leadership
• Radiation Oncologist, A/Prof Matthew Foote announced as Icon Group’s Deputy Chief Medical Officer – strengthening our global medical leadership.
• King’s Birthday Honours - Radiation Oncologists, Prof Michael Poulsen AM – awarded Member of the Order of Australia for his significant service to radiation oncology as both practitioner and researcher, and Prof Gerald Fogarty OAM – awarded Medal of the Order of Australia for his service to medical research.
• Director of Medical Oncology (AU/NZ) and Medical Oncologist, A/Prof Louise Nott was a finalist in the 2025 Australian of the Year Awards for Tasmania.
L-R: A/Prof Matthew Foote, Prof Gerald Fogarty OAM, Prof Michael Poulsen AM and A/Prof Louise Nott
Partnerships and improving care beyond treatment
• Icon’s Survivorship Program continued to expand to more Icon Cancer Centre locations nationally to support patients during and after treatment.
• The program was recognised with the 2024 Australian Private Hospitals Association (APHA) Award for Consumer Partnership and Engagement.
• In partnership with Bowel Cancer Australia, specialist Bowel Care Nurses were appointed in New South Wales, Queensland, South Australia and Tasmania to support patient navigation and education.
• A national campaign was launched with Rare Cancers Australia to raise awareness and advocate for better outcomes for people with rare and less common cancers.
• Built on our long-term partnership with Prostate Cancer Foundation (PCFA) to fully fund 10 new specialist prostate care nurse positions (beginning FY26) and invest in patient support initiatives to support men living with prostate cancer.
• Announced a partnership with Omico, experts in molecular profiling to expand access to precision oncology and clinical trials for Australian cancer patients.
Deputy Director of Nursing, Linda McGinn accepting APHA Award for Icon’s Survivorship Program.
Slade Pharmacy and Slade Health: Strengthening services
Pharmacy and compounding services across Australia and New Zealand continued to scale, supporting hospitals and improving access to critical medications.
*Icon Group provides services to support the operations of Slade Pharmacy.
Slade Pharmacy milestones
• Celebrated 60 years of excellence, reflecting Slade’s strong legacy in hospital pharmacy and compounding.
• Completed the national rebrand of Slade Pharmacy, delivering a unified national pharmacy network.
• Opened Slade Pharmacy Adeney at Adeney Private Hospital in Victoria, offering convenient services including no-gap options for eligible patients.
• Upgraded Slade Pharmacy Box Hill New South Wales to improve patient experience and service capacity.
• Announced a new Slade Pharmacy in Bendigo, continuing the focus on regional access.
• Rollout of ChartFlow, Slade’s proprietary digital medication ordering tool enhancing safety, visibility and workflow efficiency through real-time orders and dispensary monitoring.
• Received group-wide provisional accreditation to deliver the Advanced Pharmacy Australia (AdPha) Resident Training Program across our national pharmacy network. Highlighting a commitment to improving patient care and supporting professional development of early-career pharmacists.
Slade Health compounding leadership
• Slade Health now produces more than 1.3 million sterile products each year for over 200 hospitals across Australia and New Zealand.
• Integration of Charm Evolution across all public hospital sites in Victoria and Queensland marking a major milestone towards a fully digital, paperless ordering system for hospital pharmacy services.
• Celebrated one year of service at Slade Health Woodville in South Australia. Since opening, the team has prepared and dispatched more than 650 compounded products daily, totalling 53,000 essential medications.
• Te Toka Tumai, Auckland deployed a bespoke electronic prescribing tool - Raurau Nagehe at Avondale, New Zealand. Slade worked alongside the Raurau team to develop the integration improving patient safety and the hospitals clinical system and providing operational efficiencies for pharmacies.
• Slade’s Drug Stability Lab continued to increase shelflife of compounded medications delivering care to more remote regions.
Slade Pharmacy Maitland team with new Slade Pharmacy branding
Slade Pharmacy Box Hill reopening
Slade Health Woodville team one year anniversary
Sue’s (Specialist Bowel Care Nurse) support has been invaluable, and she has played a major part in me getting through and dealing with my cancer journey. From the moment we were introduced, Sue has been in constant touch, lining me up with stoma nurses before and after my operation, researching physiotherapists and dieticians to help my recovery, and she put me in touch with Cancer Council for any further assistance I may need. I can’t thank her enough.”
Karen Worcester, patient at Icon Cancer Centre Mackay, Queensland
Read Karen’s story
Strengthening our footprint across Southeast Asia
In FY2024/25, Icon deepened its presence in Asia through strategic partnerships and service expansion. With a growing network across Southeast Asia, we are committed to delivering world-class cancer care, advancing education, and improving outcomes in the region.
This year also marked a shift in our long-term growth strategy, with the divestment of our Hong Kong operations to sharpen focus on ASEAN markets and the United Kingdom. Our growth across Southeast Asia reflects our commitment to investing in partnerships that deliver sustainable, high-quality cancer care. By combining local expertise with global standards and a proven model of care, we are helping communities across the region access the care they need, close to home. As we move forward, our focus remains on strategic growth, capacity building, and cross-border collaboration to meet the evolving needs of patients across Asia.
CANCER CARE HIGHLIGHTS
Icon Cancer Centre Bali, Indonesia
• Treated our first patient at Icon Cancer Centre Bali, located at the newly opened Bali International Hospital, situated within the Sanur Special Economic Zone (SEZ), marking the first time international doctors can practice in Indonesia.
• This milestone marked Icon’s entry into Indonesia, bringing advanced and collaborative cancer treatment services to an area with growing healthcare demand.
• The centre offers radiation therapy using the latest technology and is part of a long-term partnership with Bali International Hospital to support regional capability-building and workforce development.
Icon Oncology, Penang, Malaysia
• Completed the first full year of operations in partnership with Sunsuria Healthcare and Island Hospital.
• Delivered comprehensive medical oncology and chemotherapy services to the local community and introduced Icon Singapore’s Young Women’s Cancer Program.
• The site has laid strong foundations for future service expansion and innovation in Malaysia’s northern region including the opening of a centre in Kuala Lumpur at IHH’s Prince Court Medical Centre.
Icon Cancer Centre Bali team with first patient.
Icon Oncology Penang team celebrating their first anniversary.
SINGAPORE HIGHLIGHTS
• Extended our collaboration with 365 Cancer Prevention Society, supporting public awareness, screening and early detection initiatives across Singapore - including ongoing support of their #My1stMammo and #My1stColonosopy screening campaigns which achieved a 268% and 19% increase in completed screenings respectively since 2024.
• Icon Cancer Centre Singapore was awarded AustCham’s Business Excellence Award, recognising our leadership in healthcare delivery and cross-border innovation.
Collaboration and advocacy
• Strengthened oncology education and training programs across Southeast Asia, including collaborative events and knowledge exchanges for nurses, pharmacists, and clinicians.
• Supported patient advocacy groups (PAGs) across the region, enhancing community engagement and access to education, screening and support services.
• Teams across Asia and Australia collaborated through global staff mobility programs, including clinical and support placements in Bali.
• These cross-border exchanges help foster skill development and alignment of clinical best practices, supporting local talent development while maintaining high-quality care standards.
Icon ASEAN CEO, Serena Wee receives AustCham’s Business Excellence Award 2024.
Delivering care, closer to home
Don’t wait. Don’t put off the things that really matter. Spend time with your family. Do the things you want to do. Make sure, at the end of the day, you don’t leave with regrets.”
Edmund Nai, patient at Icon Cancer Centre Singapore
Read Edmund’s story
Patient, Edmund with Dr Shang Yeap Heng Oon.
The staff across all areas within the clinic made such an effort to get to know each person. They even played whatever music I requested during my treatment. And one of the best unexpected gains from radiation therapy is making a friend.”
Katrina, patient at Icon Cancer Centre Noarlunga, South Australia
Read Katrina’s story
Care that feels like family
Imelda’s story
Finding strength and joy in the fight against Thymoma
Icon ASEAN patient, Imelda shares her story. A reminder of the difference we make to people and communities.
In 2014, my life changed forever. I was diagnosed with thymoma, a rare form of cancer, and my doctor at that time told me that I had only two months to live if I didn’t undergo surgery. At that moment, fear and uncertainty overwhelmed me, but I also made a choice: I would fight.
The questions people often ask me are, “What did it feel like? How did you get cancer?” Looking back, the initial signs were subtle yet alarming - shortness of breath, drooping eyelids, and the inability to speak for more than 10-20 minutes. My facial muscles, especially on the right side, would tire easily. These symptoms pointed to myasthenia gravis, a rare neuromuscular disease that often accompanies thymoma. To add to the challenge, I was also dealing with an autoimmune disorder.
The best medicine is a joyful heart.”
The journey begins
In June 2014, I met Dato’ Dr. M. Amir Shah, a caring and highly skilled radiologist and oncologist.
“I’ve never handled a thymoma case like yours before,” he said, “but we will do our best.
“The best medicine is a joyful heart.”
Those words became my mantra as I embarked on a gruelling treatment regimen: 12 cycles of chemotherapy and 33 sessions of radiation. By some miracle, the treatments worked, and I was cancerfree by 2018.
But cancer is a relentless adversary, testing not only the body but also the spirit. In 2018, I faced yet another battle as thymoma made its unwelcome return. This time, I endured an intense treatment regimen that included four rounds
of chemotherapy and 20 sessions of radiation. The journey was gruelling, but once again, I emerged victorious, defeating the cancer for a second time.
Yet, the struggle was far from over. In 2023, the cancer came back for a third time—a devastating blow after years of fighting. Despite undergoing six rounds of chemotherapy, the cancer showed no signs of retreat. Those months were emotionally and physically draining, filled with uncertainty and the constant fear of what lay ahead.
Finally, in January 2024, hope was restored. After undergoing seven additional chemotherapy sessions and five focused radiation treatments at Icon Cancer Centre in Island Hospital, Penang, a PET scan in October 2024 confirmed that I was cancerfree once more.”
Support in my time of need
Cancer is exhausting, painful, and at times, defeating. Yet, through every stage of this journey, Dato’ Dr. M. Amir Shah and his team have stood by my side. His genuine care, expertise, and constant availability made the unbearable seem possible. Even when I texted him late at night, he would always respond promptly, offering guidance and reassurance. Dato’ Dr. Amir’s unwavering dedication has been instrumental in my 10-year fight against thymoma.
Lessons from my experience
After a decade of battling cancer, here are a few lessons I’ve learned that may help others navigating similar struggles:
Make peace with cancer
Accepting your diagnosis is the first step. Anger, sadness, and disappointment are natural, but they won’t help you heal. Instead, focus on facing the journey with a sense of calm and acceptance.
Control your emotions
Chemotherapy often leaves you feeling irritable and uneasy. When these feelings arise, remind yourself — and those around you — that it’s the medication talking. Communication is key to maintaining relationships during such a difficult time.
Strive for independence
While it’s important to accept help, try to be as self-reliant as possible. Cancer is a long battle, and relying entirely on others can take a toll on both you and them. Maintaining some level of independence can also boost your confidence and sense of purpose.
A message of hope
Cancer is a formidable opponent, but it is not invincible.
My journey has taught me that with the right support system, a resilient spirit, and a “joyful heart,” it is possible to overcome even the most daunting challenges.
To those who are currently battling cancer, remember: you are stronger than you think. Surround yourself with people who uplift you, trust your medical team, and never lose hope. Life, even amidst the darkest storms, is worth fighting for.
This is my story, and I hope it inspires others to keep fighting.
L-R: Imelda with Dato’ Dr. M. Amir Shah in 2014 and the pair celebrating remission 10 years on.
United Kingdom
A foundational year of expansion and investment
FY2024/25 marked a pivotal year for Icon in the United Kingdom. Through major acquisitions and new partnerships, we laid the groundwork for long-term service delivery and innovation in cancer care and pharmaceutical manufacturing.
We strengthened our strategic presence in the UK, formalising our long-term partnership with Nuffield Health, acquiring their flagship cancer treatment site in London, and making a significant entry into compounding through the acquisition of Pharmaxo Group.
Icon’s entry into the UK has established a strong platform for future growth in both cancer services and compounding. With new centres underway and a significant investment in technology and infrastructure, we are well-positioned to meet rising demand and deliver exceptional care to more patients across the United Kingdom and Europe.
CANCER CARE HIGHLIGHTS
Icon Cancer Centre – London
• Acquired Nuffield Health’s Cancer Centre London, rebranded to Icon Cancer Centre – London.
• The centre provides world-class care and serves as a flagship location to support broader expansion across the UK.
Foundations for growth and exceptional patient care
New Icon centres announced
• Confirmed development of three new Icon Cancer Centres at Nuffield Health hospitals in Brighton, Derbyshire and Warwickshire.
• These centres will address the growing demand for private cancer services in underserved regions.
• Patients in these areas currently travel an average of two hours round trip for private radiotherapy. The new centres will improve access, reduce wait times, and provide choice for patients with private insurance or self-funded care.
Artist’s impressions of Icon Cancer Centre locations at Nuffield hospitals in Brighton, Derbyshire and Warwickshire.
Investment in world-class technology
• Icon Group announced a USD $18.7 million investment in cutting-edge radiotherapy equipment as part of its global partnership with Varian, a Siemens Healthineers company.
• This investment will enable the delivery of advanced techniques such as IGRT (Image-guided radiotherapy) and SBRT (Stereotactic Body Radiotherapy) across Icon’s new and existing UK sites existing UK sites to deliver first-of-its-kind technology in the region.
Doctor recognition and governance
• Icon’s UK Chief Medical Officer, Dr Penny Kechagioglou was awarded Oncologist of the Year at the Yes to Life Awards.
• Established a European Board Committee supporting Icon’s ambition to contribute expertise in cutting-edge radiotherapy and chemotherapy compounding to collaborations with the NHS and independent UK healthcare providers. The committee is an extension of the Icon Group Board and includes local respected healthcare leaders –Lord Patrick Carter and Dr Keith Ridge, CBE.
Icon UK team with Varian and Siemens Healthineers representatives.
Dr Penny Kechagioglou receiving Oncologist of the Year at the Yes to Life Awards
Lord Patrick Carter Dr Keith Ridge CBE
Compounding growth
Entry into the UK compounding and homecare market
• Acquired Pharmaxo Group, a leading UK provider of pharmaceutical manufacturing and clinical homecare services.
• This marks Icon Group’s first entry into the UK compounding market, expanding our global sterile manufacturing network.
• Began planning and integration to expand compounding capacity and services across the UK, supporting hospitals and at-home care delivery.
• Advanced the stability of monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), and cytotoxic drugs to deliver more care nationwide.
From the very first email the team made us feel seen, heard, and supported. We thought, maybe this is something we can do.
You only usually go to London for nice things – shows, sightseeing. But now it’s part of our life, and the team at CCL have become like friends to us.”
Geoff Foster, patient at Icon Cancer Centre London
Read his story
Research and Icon Cancer Foundation
Advancing research and innovation
Research remains central to Icon’s mission of advancing cancer care. Across FY24/25, we made major strides in clinical trial growth, international collaboration, and precision oncology, embedding research further into routine patient care across our global network.
Our approach is grounded in operational excellence, long-term experience, clinician engagement and strategic investment in workforce capability. We continue to expand research access across metro and regional locations, with a particular focus on Western Australia and ASEAN, to ensure patients can benefit from the latest treatments wherever they live.
RESEARCH HIGHLIGHTS
Clinical trial portfolio
• Over 200 active research projects including projects open to recruitment and in participate follow-up.
• 193 active clinical trials focused on cancer therapy across Australia, New Zealand and Singapore.
• 167 patients commenced therapy as part of a clinical trial in FY2024/25.
• 75 patients (45%) participated in Phase I (first-in-human) clinical trials, reflecting our increasing role in early-phase innovation.
Strategic recognitions and partnerships
• Joined the IQVIA Prime Site Network, strengthening clinical research infrastructure and global reach.
• First Australian organisation to receive the Global Quality Standard for Clinical Research Sites (GCSA).
• Achieved Silver Workforce Process Quality Certification (WPQC) for clinical trial operations across ANZ.
Theranostics and precision oncology
• Launched a dedicated theranostics research program, supporting the development of molecularly targeted cancer treatments.
• Expanded theranostics clinical trial activity, including trials for rare and tumour-specific cancers, providing access to innovative, precision-based care.
• Announced a dedicated theranostics and molecular imaging site in Western Australia to improve access and broaden the portfolio of treatment options available to patients, including clinical research.
Global collaborations
• Continued strategic partnerships with Varian, Omico, and leading global cancer registries and institutions.
• Supported research capability-building across ASEAN, with integrated planning between clinical services and research operations.
• Strengthened clinician-led research through global mobility and cross-site study activation processes.
Icon Cancer Foundation –Investing in future care
Icon Cancer Foundation (ICF)* plays a vital role in supporting research, education and innovation across the network. In FY2024/25, ICF delivered a range of impactful initiatives:
• Funded multiple clinician-led clinical trials, including regional and early-phase studies
• Awarded inaugural research grants supporting trial activity in South Australia and Tasmania
• Invested in key clinical and research positions, expanding research opportunities
• Facilitated community support for trials, engaging donors and patients to drive research forward.
Leadership appointment
• Appointed Dr Karthik Nath as Deputy Director of Cellular Therapy in August 2024.
• A leading medical oncologist with experience from Memorial Sloan Kettering Cancer Center, Dr Nath is leading the expansion of cellular therapies, including CAR-T and immune cell-based clinical trials across the network.
*ICF is independent from Icon Group and operates as a not-for-profit organisation.
ICF supporting Lights on the Hill Dual Memorial Convoy with special thanks to the Nolan family for their continued support.
Grant recipients Radiation Oncologist, A/Prof Peter Gorayski and Site Manager, Lydia Tamblyn and Medical Oncologist, A/Prof Louise Nott and Registered Nurse, Georgina Douglas.
There is no doubt in my mind that as a result of the treatment I have been fortunate to receive, my life has been extended far beyond what I could have expected.”
Ian Rose, patient enrolled in the TRANSFORM trial
Read Ian’s Story
Closing Summary
Icon is committed to pushing the boundaries of what’s possible in cancer research. Through our clinical trials program, global partnerships and investment in theranostics and cellular therapy, we are making tomorrow’s treatments available to patients today. The Icon Cancer Foundation continues to play a critical role in supporting this mission, enabling innovation, access and impact across the communities we serve.
Read Icon Cancer Foundation’s FY2024/25 Impact Report.
Sustainability
Our commitment to sustainability continues to grow across Patients, People, Planet, and Governance.
Our commitment to sustainable impact
Icon Group’s Sustainability Impact Report reflects our deep and ongoing commitment to care - for patients, our people and the planet. Across FY24/25, we took critical first steps in formalising our environmental, social and governance (ESG) strategy and measuring our collective impact across the communities we serve.
With global healthcare under increasing pressure, we recognise that sustainable cancer care must extend beyond the walls of our centres. Through patient-centred programs, employee-led initiatives, and climate action, we are working to provide the best care possible for patients, people and planettoday and for future generations.
CARE FOR PATIENTS
Expanding access, improving outcomes
• 16,000+ patient connections made in atrisk and underserved areas through new outreach, education, screening and clinical trial access programs.
• Patient NPS average: 95, reflecting consistent patient satisfaction and trust across our global network.
• Expanded community programs through key partnerships, including 365 Cancer Prevention Society in Singapore and rural outreach in Australia.
CARE FOR PEOPLE
Empowering a diverse, engaged workforce
• Launched Icon Insights, a new employee engagement program, with a 65% participation rate across the organisation.
• Established a Diversity, Equity & Inclusion (DE&I) baseline of 63%, setting the foundation for ongoing measurement and progress.
• Rolled out targeted programs focused on:
◦ Gender equity in leadership and clinical roles
◦ Culturally safe care for First Nations communities
◦ LGBTIQA+ inclusion and allyship
◦ Cultural awareness and multilingual resources across sites.
CARE FOR PLANET
Taking action on climate and waste
• Achieved a 49% reduction in Scope 1 and 2 greenhouse gas emissions (market-based), through energy optimisation, fuel switching, and carbon-offset initiatives.
• Increased use of renewable energy, including solar installations and green energy procurement across priority sites.
• Introduced new waste reduction and recycling initiatives, targeting pharmaceutical and packaging waste.
• Slade Health deployed electric vehicle (EV) courier fleets in major metro areas, reducing emissions by more than 45,000 kg CO2 annually.
Looking Ahead
A bold vision for the future
At Icon, we are redefining what’s possible in healthcare. With a strong mission and a proven, scalable integrated care model, we are breaking down traditional barriers and delivering innovative, patient-centred care where it’s needed most.
As we continue to grow across Australia, ASEAN, and expand into new regions, we are committed to providing world-class, personalised cancer care closer with a team that feels like family.
Together, we’re working toward a future with fewer cancer burdens and greater access to exceptional care.
Acknowledgements
We extend our deepest thanks to our patients, their families, our employees, medical specialists, research collaborators, and industry partners. Your dedication and trust drive our mission forward.
This new service is a wonderful asset for people living on the Mornington Peninsula.
“Given my age, I can’t drive anymore, so I rely on my family and friends to take me to my daily (radiation therapy) treatments. I didn’t want to travel to Frankston each day, so I decided to wait until the new centre opened.
“It’s marvellous to have such high calibre cancer treatments now available in Mornington.”
Dr Geoff Wicks, one of our first patients at Icon Cancer Centre The Bays, Victoria
Read his story
Glossary
DIBH (Deep Inspiration Breath Hold)
A radiation therapy technique for patients with breast cancer. The method requires that patients to hold their breath for a period while treatment is administered. This helps to minimise radiation exposure to the heart and lungs, as a deep breath in will cause the chest to expand and allow the vital organs to move away from the radiation field.
EACs (Energy Attribute Certificates)
Documents certifying that a company’s produced energy was generated through renewable sources (e.g. hydro, solar, wind etc).
ESG (Environmental, Social, Governance)
Icon’s environmental, social and governance principles that help to align every facet of our operations into delivering our services responsibly and sustainably. These pillars provide a framework for our sustainability efforts and helps to maximise our transparency.
GMP (Good Manufacturing Practices)
A globally recognised system of standards and principles that ensure medicines are consistently manufactured at a high quality, and are controlled to the quality standards relevant to their intended use. GMP licensed facilities meet GMP standards with validated processes and systems in place to ensure safety, consistency and quality of compounded medicines.
IGRT (Image-guided radiation therapy)
A form of radiation therapy that uses medical imaging to provide precise treatment. This imaging equipment captures high-quality X-rays to ensure the radiation is delivered where it should be.
NPS (Net Promoter Score)
In healthcare NPS is a standard measure of patient satisfaction. It is utilised to gain insight into customer experience and satisfaction. Using a 0-10 scale, it represents how likely a customer will recommend or oppose the service they receive.
RapidArc Dynamic (RAD)
Varian’s branded technology for delivering advanced VMAT (Volumetric Modulated Arc Therapy). RAD is an advanced radiation therapy technique where the machine rotates around the patient and dynamically adjusts the beam in realtime, allowing treatment to be delivered faster and more precisely than other more traditional forms of radiation therapy delivery.
SGRT (Surface Guided Radiation Therapy)
Also sometimes referred to as tattoo-free radiation therapy. SGRT is a non-invasive form of treatment that uses advanced cameras, 3D tracking and complex imaging systems to detect movement on the skin’s surface. This real-time tracking eliminates the need for permanent tattooing and increases accuracy and reduces patient treatment times.
SRT (Stereotactic Radiation Therapy)
Stereotactic radiation therapy (SRT) is also referred to as stereotactic body radiation therapy (SBRT) or stereotactic ablative radiation therapy (SABR). It is an advanced technique used to treat small, well-defined tumours or high-risk postoperative areas. It can be used to treat both primary and metastatic (sometimes referred to as secondary tumours).
Theranostics
A form of personalised cancer treatment that combines both diagnostic imaging to identify a person’s cancer cells and then use targeted therapy for their cancer. It aims to slow the growth and spread of cancer, relieve symptoms and maintain or improve quality of life.
